Also known as: CB 813
Catalyst Biosciences (Other)Targacept (Other)
Targacept and Catalyst reverse merging to form Catalyst Biosciences Inc.
Catalyst Biosciences (Licensor)Wyeth (Licensee)Pfizer (Licensee)
Catalyst granted Wyeth exclusive, worldwide rights to develop and commercialize CB 813 (PF-05280602) to treat and prevent acute bleeding in hemophilia patients
Set Email Alert